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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
IN THE TREATMENT OF ACUTE LYMPHOCYTIC LEUKEMIA (ALL) IN 126
ADULTS: IMPACT OF DONOR SOURCE ON LEUKEMIA FREE SURVIVAL
(LFS)
Kumar, Priya, Defor, Todd E., Brunstein, Claudio, Barker, Juliet N.,
Wagner, John E., Weisdorf, Daniel J., Miller, Jeffrey S., McGlave, Philip,
Slungaard, Arne, Arora, Mukta, Tomblyn, Marcie, Burns, Linda J. Blood
and Marrow Transplant Program, University of Minnesota, Minneap-
olis, MN.
White blood cell (WBC) count and speciﬁc cytogenetic abnor-
malities at diagnosis, patient age and disease status at HSCT have
previously been identiﬁed as risk factors associated with LFS in
patients with ALL. As the use of umbilical cord blood (UCB) is
relatively new, particularly for adults, we sought to evaluate the
relative impact of donor source.
In this single center study, 126 adults aged 18-61 (median 31)
years (yrs) underwent myeloablative conditioning (cyclophosph-
amide 120 mg/kg and total body irradiation 1320-1375 cGy
based regimen in 92%) followed by allogeneic HSCT. Stem cell
source was an HLA matched related donor (MRD) in 85, HLA
matched unrelated donor (URD: M) in 15, HLA mismatched
unrelated donor (URD: MM) in 14 and HLA 0-2 (A, B, DRB1)
mismatched UCB in 12. At the time of HSCT, 64 patients were
in CR1, 51 in CR2, and 11 patients in CR3; 20 patients had
T-lineage disease; 38 patients (30%) had either t (9; 22) (n 
28), t (4; 11) or t (1, 19) (n  10) with the remainder (70%)
having normal cytogenetics. WBC 30  109/L at diagnosis
was documented in 50%. Demographics, disease characteristics
at initial diagnosis and transplant variables were similar in all 4
groups except: year of transplant after 1996 and use of growth
factor for all UCB recipients.
Outcomes by donor source: As a consequence of low transplant
related mortality (TRM), overall survival (OS) and LFS were
superior after UCB transplants. In multiple regression analysis, 5
independent risk factors were signiﬁcantly associated with poorer
OS: use of URD:M (RR 3.8, 95% CI 1.1-13.8, P  0.04) and
URD:MM (RR 4.9, 95% CI, 1.3-19.1, P  0.02), CR3 at HSCT
(RR 3.0, 95% CI, 1.1-8.8, P  0.04), WBC 30  109/L (RR 2.4,
95% CI, 1.4 -4.1, P  0.01), cytomegalovirus (CMV) seropositive
recipient and donor (RR 4.0, 95% CI, 2.0-7.9, P  0.01), and 2
induction regimens to achieve initial CR (RR 2.7, 95% CI, 1.2-5.9,
P  0.01). Patients who developed grade II-IV acute graft versus
host disease (GVHD) had signiﬁcantly lower mortality rates (RR
0.4, 95% CI, 0.2-0.7, P  0.01). There was no impact on OS by
year of transplant or use of growth factor. Variables associated with
poor LFS were identical to those for OS, and GVHD was again
associated with improved LFS.
These results support the use of UCB as an alternative stem cell
source for adults with ALL, with results comparable to outcomes
observed with MRDs. In addition, GVHD is associated with im-
proved LFS suggesting a signiﬁcant graft versus leukemia effect
with all donor graft sources.
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STUDY THE IMPACT OF NUMBER AND TYPE OF HLA INCOMPATIBILI-
TIES AND CELL DOSE ON OUTCOMES OF UNRELATED CORD BLOOD
TRANSPLANTS FOR PATIENTS WITH MALIGNANT AND NON-MALIG-
NANT DISORDERS
Gluckman, E., Rocha, V. for Eurocord. Hospital Saint Louis, Paris,
France.
The objective was to study the interactions between HLA type
and number and cell dose infused with the outcomes of unrelated
cord blood transplants in order to produce prognosis indices and
determine criteria of donor choice.
One thousand patients with hematological malignancies were
analyzed. The results show that cell dose is the most important
factor for engraftment and transplant related mortality (Table 1). A
minimum of 3  107 nucleated cells/kg at collection and 2 
107/kg at infusion must be obtained. HLA mismatches increase the
risk of engraftment delays, transplant related mortality and chronic
GVH; it decreases the risk of relapse resulting in an absence of the
role of HLA mismatches for survival. The type of HLA mis-
matches did not inﬂuence the outcome but matching for DRB1
improves outcome. Most importantly, increasing cell dose abro-
gates the inﬂuence of HLA mismatches (Table 2).
In 268 patients with non malignant diseases, requirements for
cell dose and HLA matching were different in non malignant
diseases compared to malignant diseases. In non malignant dis-
eases, cell dose is higher at 4.9  107/kg at collection and 3.5 
107/kg at infusion. HLA mismatches play a major role for engraft-
ment, survival and GVH. It is partially abrogated by increasing cell
dose. Two HLA DRB1 mismatches resulted in an adverse outcome
(Table 3).
Conclusions:
● Our results show that requirements for cell dose and HLA
matching are different in malignant and non malignant dis-
eases.
● In non malignant disease, cell dose is higher with 4.9 107/kg
at collection and 3.5  107 NC/kg at collection while it is
at 3.  107/kg at collection and 2  107 NC/kg in malignant
diseases. This difference is probably due to the pretransplant
chemotherapy in malignant diseases.
● HLA mismatches play a major role for engraftment and sur-
vival in non malignant diseases while in malignant disease it
has a beneﬁcial role for preventing leukemic relapse resulting
in an absence of effect on leukemia free survival.
● HLA mismatches can be partially overcome by increasing cell
dose.
● Matching for class II is better than for class I.
Table 1. Summary of Outcomes in Umbilical Cord Blood Transplants
From Eurocord Registry
MRD URD:M URD:MM UCB P
n 85 15 14 12
Median follow-up (y) 9.3 3.5 7.2 1.2
OS 1 yr % (95% CI) 41 (31-52) 33 (9-57) 14 (0-33) 75 (51-100) 0.02
LFS 1 yr % (95% CI) 35 (25-45) 27 (4-49) 14 (0-33) 67 (40-93) 0.03
Relapse 1 yr % (95%
CI) 21 (12-30) 20 (0-40) 0 8 (0-23) 0.22
TRM 1 yr % (95% CI) 44 (33-55) 53 (27-79) 86 (57-100) 25 (1-49) <0.01
Table 2. Interaction between HLA Mismatches, Number of Cells
and Outcomes in Unrelated Cord Blood Transplants for Malignant
Diseases
Number of
HLA MM
0-1 vs 2 vs 3-4
Type of HLA
MM Class I vs II
Interaction with
Number of Cells
PMN
engraftment
Less Same Worse 3-4 mismatches and
<3  107 NC/kg
Platelet
engraftment
Less Same Worse 3-4 mismatches and
<3  107 NC/kg
TRM More More 2 DR MM Worse 3-4 mismatches and
<3  107 NC/kg
aGVHD More More 2 DR MM Same
cGVHD More Same Decreased <MM and >cells
Relapse Less Less 2 DR aMM Increased <MM and >cells
LFS, OS Same Same Decreased >MM and <cells
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